Table of Content

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Treatment
3.3. Snippet by End Users
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing Research and Developments for Bone Cancers
4.1.1.2. Rising Investments for Bone Cancer Treatment
4.1.2. Restraints
4.1.2.1. Aftereffects Associated with Chemotherapy
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter’s 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
5.5. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. By Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Primary Bone Cancer
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.2.3. Osteosarcoma
7.2.4. Chondrosarcoma
7.2.5. Ewing Sarcoma
7.2.6. Chordoma
7.3. Secondary Bone Cancer
7.3.1. Bone Metastasis
8. By Treatment
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment
8.1.2. Market Attractiveness Index, By Treatment
8.2. Surgery
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Chemotherapy
8.3.1. Doxorubicin
8.3.2. Cisplatin
8.3.3. Etoposide
8.3.4. Vincristine
8.4. Radiation Therapy
8.4.1. Proton-Beam Radiation Therapy
8.4.2. Stereotactic Radiosurgery
8.4.3. Intensity-Modulated Radiation Therapy
8.5. Targeted Therapy
8.6. Immunotherapy
8.7. Others
9. By End Users
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End Users
9.1.2. Market Attractiveness Index, By End Users
9.2. Hospitals
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Oncology Centers
9.4. Ambulatory Surgical Centers
9.5. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. U.K.
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Type
10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Treatment
10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End Users
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Product Benchmarking
11.3. Company Share Analysis
11.4. Key Developments and Strategies
12. Company Profiles
12.1. Pfizer Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. MicroBiopharm Japan Co. Ltd.
12.3. Sterling Biotech Ltd.
12.4. Teva Pharmaceuticals Industries Ltd.
12.5. Cipla Ltd.
12.6. Aspen API Inc.
12.7. Eli Lilly and Company
12.8. Gatewell Oncology Pvt. Ltd.
12.9. Recordati Rare Diseases Inc.
12.10. Novartis AG
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us